News coverage about Achaogen (NASDAQ:AKAO) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Achaogen earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7902996800776 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- Achaogen, Inc. (AKAO) stands -17.03% away from 50 SMA: Technical Watch – Voice Of Analysts (analystsbuzz.com)
- Achaogen Adds Liz Bhatt as Chief Business Officer – GlobeNewswire (press release) (globenewswire.com)
- Buy Healthcare Stock analysis: Achaogen, Inc. (AKAO) – Street Observer (press release) (streetobserver.com)
- Achaogen (AKAO) Appoints Liz Bhatt as Chief Business Officer – StreetInsider.com (streetinsider.com)
- ETFs with exposure to Achaogen, Inc. : September 18, 2017 (finance.yahoo.com)
Achaogen (NASDAQ AKAO) traded up 0.64% on Friday, hitting $15.84. The company had a trading volume of 619,412 shares. Achaogen has a 12-month low of $3.68 and a 12-month high of $27.79. The firm has a 50-day moving average price of $17.84 and a 200-day moving average price of $21.63. The firm’s market capitalization is $668.97 million.
Achaogen (NASDAQ:AKAO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.18). The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.69 million. Achaogen had a negative return on equity of 86.24% and a negative net margin of 281.88%. The business’s revenue for the quarter was down 85.7% compared to the same quarter last year. During the same period last year, the company posted ($0.87) earnings per share. On average, equities research analysts anticipate that Achaogen will post ($3.04) earnings per share for the current fiscal year.
AKAO has been the topic of several recent analyst reports. Mizuho initiated coverage on shares of Achaogen in a research note on Wednesday, September 6th. They issued a “buy” rating and a $28.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and issued a $30.00 target price on shares of Achaogen in a research note on Friday, August 4th. BidaskClub upgraded shares of Achaogen from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. HC Wainwright initiated coverage on shares of Achaogen in a research note on Thursday, June 15th. They issued a “buy” rating and a $29.00 target price on the stock. Finally, ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $26.07.
WARNING: “Achaogen (AKAO) Given News Impact Rating of 0.14” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/24/achaogen-akao-given-news-impact-rating-of-0-14.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.